Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Cash (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Change in Cash for 6 consecutive years, with -$18.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 6825.84% year-over-year to -$18.9 million, compared with a TTM value of $1.6 million through Dec 2025, up 103.37%, and an annual FY2025 reading of $1.6 million, up 103.37% over the prior year.
  • Change in Cash was -$18.9 million for Q4 2025 at SAB Biotherapeutics, down from $25.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $54.1 million in Q4 2023 and bottomed at -$42.5 million in Q1 2024.
  • Average Change in Cash over 5 years is -$105385.2, with a median of -$2.6 million recorded in 2023.
  • The sharpest move saw Change in Cash skyrocketed 33841.08% in 2021, then crashed 6825.84% in 2025.
  • Year by year, Change in Cash stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.3% to $54.1 million in 2023, then plummeted by 100.5% to -$273209.0 in 2024, then plummeted by 6825.84% to -$18.9 million in 2025.
  • Business Quant data shows Change in Cash for SABS at -$18.9 million in Q4 2025, $25.7 million in Q3 2025, and -$1.9 million in Q2 2025.